Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Download
Standard view
Full view
of .
Look up keyword
Like this
1Activity
0 of .
Results for:
No results containing your search query
P. 1
Pfizer Business Report - Aileen Marshall

Pfizer Business Report - Aileen Marshall

Ratings: (0)|Views: 2,359|Likes:
Published by Aileen

More info:

Categories:Types, Research
Published by: Aileen on May 22, 2010
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as DOC, PDF, TXT or read online from Scribd
See more
See less

10/05/2014

pdf

text

original

 
   A  p  r i l  2  2 ,  2  0  1  0
28
 
SLIS J748, Spring 2010 - Dr. Kendra AlbrightBusinessReport - Pfizer Inc., prepared by Aileen MarshallCAN PFIZER MAINTAIN SUCCESS IN THE U.S. PHARMACEUTICAL INDUSTRY?Table of Contents:A.
Executive summary
 
B
. Company snapshot
C.
Analysis of Pfizer’s current position in relation to the market
PEST Analysis
SWOT Analysis 
D
. Conclusion 
E.
Bibliography
F.
Appendices
A. Executive Summary
This report summarizes and analyses the pharmaceutical company Pfizer, the currentmarket and the company's position within it. Pfizer is the leading pharmaceutical firm and,after the acquisition of Wyeth, the largest research-based company. Its mission is toprovide accessible quality health care and products to all consumers. Despite the currenteconomy, Pfizer is still in a strong position with a growth in sales and employees in 2009,after a drop in revenue in 2008. The market outlook seems to be positive, despite manythreats that the company will face over the coming years, such as loss of patents and globalpricing pressure.Sales are likely to increase as more Americans will be insured under the new healthcare bill. However, generic and OTC drugs gain popularity among the population, so
 
   A  p  r i l  2  2 ,  2  0  1  0
28
 
SLIS J748, Spring 2010 - Dr. Kendra AlbrightBusinessReport - Pfizer Inc., prepared by Aileen Marshall
Pfizer will face severe competition. To counter this, the firm will have to stop depending somuch on their leading brand products, and explore emerging markets. Although Pfizerexpects some of its newest drugs to be approved in the near future, new regulatorylegislations will have an impact on the approval process and time, resulting in higher costsand a loss of revenue. Pfizer will therefore have to cut costs and expand into new niches,which can be achieved by mergers and acquisitions as well as strategic agreements withother companies to make research more efficient and cost effective.This report will present a company snapshot, followed by an analysis of the currentmarket situation and then looking at internal and external factors that influence Pfizer'sposition.
B. Company Snapshot
Pfizer Inc. is a public pharmaceutical company with currently 116,500 employees,located at 235 E. 42nd Street, New York, NY 10017-5755. Part of the New York StockExchange, the ticker symbol for Pfizer is PFE, primary SIC code
Pharmaceutical preparations(2834),
primary NAICS code
Pharmaceutical and Medicine Manufacturing (32541).
1
It is theparent company to more than 30 subsidiaries.
2
The company is the world's largest research-based pharmaceutical firm, and aims toapply science and global resources to improve health and well-being of all people at everystage of life. It also claims to be a leading voice for improving everyone's ability to havereliable and affordable health care. Striving to set standards for quality, value, and safety,Pfizer develops medicine for humans as well as animals. Their health care portfolio
1
LexisNexis Business (2010)
2
See Appendix A for a complete list.
 
   A  p  r i l  2  2 ,  2  0  1  0
28
 
SLIS J748, Spring 2010 - Dr. Kendra AlbrightBusinessReport - Pfizer Inc., prepared by Aileen Marshall
includes biologic and small molecule medicines, vaccines, nutritional products and manywell-known consumer products.
3
The latter include the erectile dysfunction treatmentViagra, pain management drugs Celebrex and Lyrica, depression management drug Zoloft,the popular ChapStick, cholesterol-lowering Lipitor, and more.
4
The company's maincompetitors include Bayer AG, Merck, Novartis, Proctor and Gamble, and Johnson & Johnson, among others.
5
 Notable acquisitions and mergers include the purchase of the drug maker Roerig in1953, SmithKline Beecham's animal health business in 1995, Procter & Gamble's Bain deSoleil skin care line and Warner -Lambert in 1999, its rival Pharmacia in 2003 ($54 billion),the research division of QuoreX and Esperion Therapeutics in 2004, Vicuron Pharmaceuticalsin 2005 (which was divested again in 2009)
6
, and pharma rival Wyeth in a $68 billion deal in2009, making this the largest merger of pharmaceutical companies in nearly a decade.
7
There is also a rumor that Pfizer is seeking a buyer for its division of experimental drugs,which include over 100 drugs that treat conditions such as high cholesterol and obesity. Asof July 23, 2009 there has not been named an interested buyer to acquire this asset.
8
According to Hoover's, Pfizer made $50,009 million in sales in 2009. The followingtable summarizes the percentage of sales in different regions.
3
Pfizer
4
See Appendix B for a complete list of products.
5
LexisNexis Business(2010)
6
Hoover's (2010)
7
TFSD Worldwide M&A (2010)
8
ibid

Activity (1)

You've already reviewed this. Edit your review.
1 thousand reads
1 hundred reads
Nurul Azim liked this
Nurul Azim liked this
Nurul Azim liked this
Nurul Azim liked this
Nurul Azim liked this
Nurul Azim liked this
Nurul Azim liked this

You're Reading a Free Preview

Download
scribd
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->